licensing

News

Takeda joins PIKfyve ALS push with AcuraStem deal

Takeda has bolstered its neuroscience pipeline by licensing drug candidates from California biotech AcuraStem targeting PIKfyve, which is gathering attention as a drug tar

News

Roche buys into Alnylam's twice-yearly blood pressure drug

Roche has paid $310 million upfront for rights to Alnylam Pharma's zilebesiran for hypertension, a handsome sum for a drug that so far has only generated phase 1 data.

News

Haleon nabs rights to Futura’s OTC erectile dysfunction gel

Just over a month after getting FDA approval for the first over-the-counter (OTC) topical therapy for erectile dysfunction (ED), Futura Medical has lined up some heavyweig

News

BMS takes option on Prothena Alzheimer’s drug in $2.2bn deal

Bristol-Myers Squibb has upgraded a long-running alliance with Prothena in Alzheimer’s disease, taking an option on a tau protein-targeting antibody in early-stage clinica

News

J&J snaps up Nanobiotix cancer radiotherapy in $2.5bn+ deal

Johnson & Johnson has bolstered its oncology pipeline by licensing a drug from Nanobiotix designed to enhance the effectiveness of radiotherapy for solid tumours.

News

Kate helps Astellas double up on XLMTM gene therapy

Astellas’ gene therapy for rare disease X-linked myotubular myopathy (XLMTM) has been hampered by safety concerns, so its decision to license an alternative from start-up

Takeda joins PIKfyve ALS push with AcuraStem deal

Roche buys into Alnylam's twice-yearly blood pressure drug

Haleon nabs rights to Futura’s OTC erectile dysfunction gel

BMS takes option on Prothena Alzheimer’s drug in $2.2bn deal

J&J snaps up Nanobiotix cancer radiotherapy in $2.5bn+ deal

Kate helps Astellas double up on XLMTM gene therapy

On the future of AI in life sciences, with women at the helm

How to meet your physicians where they are online

licensing

Editor's Picks